- Entry
- $58.33
- Now
- $58.26 -0.1%
- Target
- —
- Score
- —
WSB deleted this, mods must own a boatload of EXEL. All this is my own work by hand, no AI slop. $EXEL is a pharma company that relies on a single product for basically all of their revenue: cabozantinib (brand name CABOMETYX), which is a cancer drug. It currently brings about $2B a year. The shares are near ATH right now ($59), with analyst targets of $41-66. So you might think it's overvalued already (15B market cap on 2B annual …
— ORIGINAL POST ·
DD: $EXEL Short Opportunity
· r/stocks
· Sep 9, 2026